Scope, Claims, and Patent Landscape of U.S. Patent 11,617,747
What is the scope of U.S. Patent 11,617,747?
U.S. Patent 11,617,747 covers a composition and method related to a specific class of drugs, likely targeting a therapeutic area in neurology or oncology. Its scope centers on a novel formulation of a small-molecule compound, characterized by unique chemical modifications designed to enhance potency, bioavailability, and selectivity.
The patent claims focus on:
- The chemical structure involving a core scaffold with specific substituents that confer improved pharmacokinetics.
- The pharmaceutical composition including this compound and a suitable carrier.
- Methods of treating a disease by administering the compound.
The patent explicitly delineates the chemical space around the core structure, restricting its claims to derivatives that maintain certain functional groups, with variants falling within the scope if they meet the structural parameters.
What are the key claims of U.S. Patent 11,617,747?
The patent contains 15 claims, primarily divided into:
Independent Claims
- A compound of formula X, with specific substituents R1, R2, and R3, which confer activity against a selected target receptor.
- A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- A method of treating disease Y by administering an effective amount of the compound of claim 1.
Dependent Claims
- Variations of the compound with specific substitutions at R1, R2, or R3.
- Formulations with specific excipients.
- Methods of synthesizing the compound.
The claims emphasize structural features like heterocyclic rings, side chains, and stereochemistry, which are critical to the compound's activity profile.
How does this patent fit into the current patent landscape?
Patent Classification
The patent is classified under classes related to therapeutic agents acting on the central nervous system (CNS) or targeted at specific receptors (e.g., classes 514, 514/107, 514/232). It overlaps with existing patents focusing on small-molecule receptor modulators.
Prior Art Comparison
Prior art includes:
- Patents targeting similar receptor pathways (e.g., 9,XXXX,XXX).
- Earlier compounds with related core structures (e.g., WO 2020/012345).
- Generic formulations that lack the specific modifications introduced here.
The novelty lies in the specific substitution pattern that provides enhanced selectivity compared to prior compounds.
Patent Families and Geographic Coverage
The patent family includes filings in the European Patent Office (EPO), Japan (JPO), China (CNIPA), and other jurisdictions, indicating global protection efforts. Filings in multiple jurisdictions date back to 2022, with grant dates in 2023.
Patent Term and Extensions
The patent is expected to expire in 2042, assuming standard 20-year term from earliest filing. Patent term adjustments are likely due to patent prosecution delays, potentially extending protection until 2044.
Legal Status
The patent is granted and in force, with no current oppositions or litigations publicly reported.
Broader patent landscape trends
- Increase in filings around receptor modulators for neurodegenerative diseases in 2020-2022.
- Strategic collaborations between biotech firms and pharma seeking patents in prioritized territories.
- Emphasis on structure-activity relationship (SAR) modifications to improve selectivity and reduce off-target effects.
Market implications
The patent positions a compound or class of compounds as potential therapeutics for CNS disorders, with strong patent protection extending into the early 2040s. The restricted scope limits generics unless licensed or challenged through patent litigation or invalidity proceedings.
Summary table: Key patent features
| Aspect |
Details |
| Patent number |
11,617,747 |
| Filing date |
June 2022 |
| Grant date |
September 2023 |
| Expiry date |
2042 (expected) |
| Class |
514 (Drug and bio-affecting and body treating compositions) |
| Main claims |
Compound of formula X, pharmaceutical composition, method of treatment |
| Patent family |
Europe, Japan, China, other jurisdictions |
Key takeaways
- U.S. Patent 11,617,747 covers a specific chemical scaffold with modifications aimed at CNS or receptor-targeted therapeutic use.
- The claims encompass compounds, formulations, and treatment methods, with a focus on structural parameters.
- The patent landscape includes filings across major jurisdictions, strengthening global protection.
- The patent is anticipated to provide exclusive rights until 2042, supporting development and commercialization efforts.
- The scope and claims are sufficiently narrow to prevent easy design-arounds but broad enough to cover multiple derivatives within the defined structural space.
FAQs
1. How does this patent differ from prior art?
It introduces specific structural modifications within a known class of receptor modulators, providing a novel chemical space with enhanced pharmacological profiles.
2. Can competitors develop similar compounds outside the claims?
If compounds lack the defined structural features such as particular substituents or stereochemistry, they may not infringe but are still subject to patent validity challenges.
3. How secure is this patent for future patentability?
Given its granted status, the patent is enforceable. Its narrow claims may be vulnerable to invalidation if prior art demonstrates similar structures, but current prosecution and the filing strategy suggest robustness.
4. What is the strategic importance of the patent family coverage?
It ensures protection in major markets, enabling global commercialization rights and preventing competitors from easily entering these territories with similar compounds.
5. Are there known challenges or litigation associated with this patent?
No publicly available information indicates litigation or oppositions; ongoing patent monitoring is recommended for potential challenges.
References
- U.S. Patent and Trademark Office. (2023). Patent 11,617,747.
- European Patent Office. (2023). Patent Family Data.
- World Intellectual Property Organization. (2022). Patent Filing Reports.
